While shares of Novo Nordisk rose 3.3 percent Tuesday on the news that the FDA had approved its once-daily injectable glucagon-like peptide-1 (GLP-1) receptor agonist Victoza (liraglutide) for Type II diabetes, it was competitors Amylin Pharmaceuticals Inc. and Alkermes Inc. whose stock benefitted the most, surging 9 percent and 7.2 percent, respectively. (BioWorld Today) Read More
